Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

A Case Against CVS Health Corporation Is Being Pursued For Securities Law Violations And Investors Are Encouraged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation Is Being Sued For Securities Fraud And The Schall Law Firm Invites Stockholders To Join

NEW YORK, Aug. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages CVS Health Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVS

LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Are Encouraged By The Schall Law Firm To Take Part In A Lawsuit Against CVS Health Corporation For Securities Law Violations

NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CVS investors who were adversely affected by alleged securities fraud between May 3, 2023 and April 30, 2024.

CVS Health Corporation Class Action: Levi & Korsinsky Reminds CVS Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 - CVS

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit.

Investors who lost money on CVS Health Corporation (CVS) should contact Levi & Korsinsky about pending Class Action - CVS

LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

The Schall Law Firm Invites Shareholders To Participate In A Securities Fraud Case Against CVS Health Corporation

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS).

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 10, 2024 in CVS Lawsuit – CVS

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CVS Health Corporation (NYSE: CVS) securities between May 3, 2023 and April 30, 2024, all dates inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the CVS class action lawsuit. Captioned Nixon v. CVS Health Corporation, No. 24-cv-05303 (S.D.N.Y.), the CVS class action lawsuit charges CVS as well as certain of CVS's top current and former executives with violations of the Securities Exchange Act of 1934.

CVS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that CVS Health Corporation Investors with Substantial Losses Have Opportunity to Lead Case

NEW YORK CITY, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired CVS securities between May 3, 2023, and April 30, 2024, inclusive (the "Class Period").

CVS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds CVS Health Corporation Investors to Join the Class Action Lawsuit!

LOS ANGELES, CA / ACCESSWIRE / August 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Are Urged To Join The Schall Law Firm In The Securities Fraud Lawsuit Against CVS Health Corporation

Artwork represents artists' mental health and wellness journeys WOONSOCKET, R.I. , Aug. 21, 2024 /PRNewswire/ -- CVS Pharmacy® (NYSE: CVS), the retail division of CVS Health®, today unveiled a new collection of journals featuring cover designs inspired by the mental health and wellness journeys of four CVS Health colleagues.

CVS Pharmacy® introduces colleague-designed journals

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., August 20, 2024. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CVS Health Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVS

Ares Capital

Bank of Nova Scotia

HSBC Holdings

Altria

Realty Income Corp

PepsiCo

Vici Properties

Verizon

Allianz SE

Today, I will present you with 10 dividend income-producing companies to consider investing in during this month of August. Each carefully selected company pays an attractive dividend, holds potential for dividend growth, and has an attractive Valuation. By effectively combining high dividend yield companies with those that have strong dividend growth potential, investors can maximize their benefits, an approach utilized by The Dividend Income Accelerator Portfolio.

My Top 10 High Dividend Yield Companies For August 2024

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=96828&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on CVS Health Corporation (CVS) Should Contact Levi & Korsinsky About Pending Class Action - CVS

LOS ANGELES, CA / ACCESSWIRE / August 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of §§10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders Invited To Participate In CVS Health Corporation Securities Fraud Lawsuit With The Schall Law Firm

Bristol-Myers

Dow Inc

Bristol Myers Squibb doesn't sell anti-obesity drugs, but it can keep raising its dividend payout without them. Shares of Dow Inc. offer a yield above 5%, and there's a good chance the company can begin raising its payout again.

3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in CVS Health Corporation ("CVS" or the "Company") (NYSE: CVS) of a class action securities lawsuit.

CVS Health Corporation Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CVS

LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of §§10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Urged To Join CVS Health Corporation Securities Fraud Suit With The Schall Law Firm

NEW YORK , Aug. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CVS Health Corporation (NYSE: CVS). Shareholders who purchased shares of CVS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

CVS Health Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights - CVS

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of §§10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Shareholders Encouraged To Participate In The CVS Health Corporation Securities Fraud Lawsuit With The Schall Law Firm

Walgreens

Retail pharmacy chains such as Walgreens and CVS have pivoted from years of endless store expansions to shuttering hundreds of locations across the U.S. to shore up profits.  Among the biggest problems has been falling reimbursement rates for prescription drugs and several factors pressuring the front of the store, such as inflation and increased competition.

Here's why Walgreens and CVS retail pharmacies are struggling — and what they're doing to fix it

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of §§10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Investors Invited To Join The CVS Health Corporation Securities Fraud Suit With The Schall Law Firm

NEW YORK, Aug. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CVS Health Corporation (NYSE: CVS) between May 3, 2023 and April 30, 2024, both dates inclusive (the “Class Period”), of the important September 10, 2024 lead plaintiff deadline.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages CVS Health Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – CVS

NEW YORK, NY / ACCESSWIRE / August 16, 2024 / If you suffered a loss on your CVS Health Corporation (NYSE:CVS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cvs-health-corporation-lawsuit-submission-form?prid=96150&wire=1 or contact Joseph E. Levi, Esq.

News for CVS Health Stock (CVS)